Search

The article offers information on Chinese contract research organization (CRO) WuXi AppTec headquartered in Shanghai, China. Topics discussed include insights of founder and chief executive officer (CEO) Gi Li regarding the company, the research and development (R&D) laboratories of the organization, and the money raised by WuXi AppTec for its venture capital fund.

The article reports on the influx of chemical and pharmaceutical laboratories in Shanghai, China. A research and development center will be inaugurated by Dow Chemical that will employ 1,000 people by 2010. Degussa is building additional space for 60 new scientists at its research and development facilities because the laboratory it opened in 2004 for 100 scientists is fully utilized.

The article announces the explosion of a benzene tank while repairing undertaken by Aijinke Engineering Construction Service, on May 12, 2018 at the Secco Petrochemical facility in Shanghai killing six people.

The article discusses the annual Innovation Summit on drug discovery and pharmaceutical firms in China at the Zhangjiang Hi-Tech Park in Shanghai, China on November 16, 2016.

The article offers information on the opening of a corporate research laboratory in Shanghai, China. It informs that employees at the Shanghai center will conduct fundamental research and will also provide technical support for the customers in China and Asia. It also informs that the research will focus on advanced materials that are used in construction, footwear, personal care and energy-efficient lighting.

The article focuses on research and development (R&D) facilities at the Zhangjiang Hi-Tech Park in Shanghai, China which became a suitable location for chemical companies including AstraZeneca, GlaxoSmithKline and Novasep. It states that majority of the drug multinational companies in the industrial park never laid off employees despite of rising cost of doing business. The industrial park has a tram service for its employees.

The article provides information on a new ExxonMobil Chemical R&D center in Shanghai, China. The $70 million R&D center of ExxonMobil Corp. will initially employ 70 scientists but will be large enough to accommodate 200. The facility, which should be fully operational before end of the year, will offer technical support for the company's customers throughout Asia.

The article reports that drug maker Eli Lilly & Co. has partnered with Hutchison MediPharma in Shanghai, China. Executives involved in the Eli Lilly-MediPharma partnership believe that the alliance is about sharing the risks and rewards of pharmaceutical research. Eli Lilly has decided that MediPharma is capable of achieving breakthroughts in pharmaceutical research. Comments from Eli Lilly vice president of global externa research and development Robert W. Armstrong are included.

Reports on the construction status of the Secco petrochemical complex in Shanghai, China. Partnership between British Petroleum (BP), Sinopec and Shanghai Petrochemical Co.; Focus of the project on the importance of job-site safety; quality cost and schedule; Management of the BP-Sinopec venture by Gordon Souter; Project completion schedule; Impact of Chinese construction strategies and availability of skilled labor on the rapid construction progress; Overview of the project's contract preparation.

The article discusses second annual Asian conference and trade show of nonprofit organization Society for Laboratory Automation and Screening that was held in Shanghai, China in June 2012. The conference featured academic scientists from U.S. universities and scientific managers of multinational drug companies. The trade show offered an occasion for the equipment vendors and local scientists to understand each other.

The article reports that Eli Lilly & Co. has sent a group of scientists in Shanghai, China to administrate the Chinese firms the company has tasked with research and development programs. Lilly vice president Robert W. Armstrong states that the move is one way of improving the company's status in the market. An overview of the issues which emerged with the company's expansion is presented.

The article discusses the growth of Medicilon, a drug developer launched in 2004 by Jintao Zhang, Chunlin Sheng, and Cheney Mao in Shanghai, China. It notes that the increase is partly driven by the wide range of services the company offers its customers. These services include biology services and toxicology studies. Customers like Sitris Pharmaceuticals can work with Medicilon either on a project basis or by hiring the company's staff as full-time equivalents (FTE).

The article reports on the relocation of the Woburn, Massachusetts-based chemical research and development company Alputon to Shanghai, China. Alputon was established to offer a wider range of drug discovery services than the compound library synthesis provided by its founders who worked and developed a chemistry technology platform at ArQule. Details about business operations and strategies are cited.

Reports that state-owned China Worldbest Group has become China's largest pharmaceutical conglomerate. Change in focus from textile and agricultural machinery to pharmaceuticals; Response to rapid social and economic changes in Shanghai; Rise in incomes resulting in more demand for health products; 2002 acquisition of a controlling 40 percent stake in state-owned Shanghai Pharmaceutical.